Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 13 May, 2009

Lipoxen PLC

Malaria Vaccine Agreements

RNS Number : 1447S
Lipoxen PLC
13 May 2009

For immediate release

13 May 2009

Lipoxen PLC

('Lipoxen' or 'the Company')

Agreements with the PATH Malaria Vaccine Initiative and US NIAID

Preclinical feasibility project to determine ability of Lipoxen's Liposomal
Technology to stimulate enhanced immune responses against malaria protein 

Lipoxen PLC (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that the Company has received funding to apply its ground-breaking ImuXen® technology to enhance the performance of malaria vaccine candidates. The PATH Malaria Vaccine Initiative, a program of the non-profit organization, PATH, will provide funding for the project. Scientists from the US National Institute of Allergy and Infectious Diseases (NIAID), a component of the US National Institutes of Health, will provide expertise to the project, which is anticipated to report results in mid-2010.

The project will apply Lipoxen's patented technology with a view to improving the ultimate performance and efficacy of malaria vaccines. Lipoxen will be responsible for the development of an optimised malaria vaccine formulation, while NIAID scientists will be responsible for evaluating its activity in a relevant pre-clinical model.

Lipoxen's proprietary ImuXen® technology is based on the use of natural substances found in the human body (liposomes) to entrap the active ingredients (a malaria antigen in this project) to ensure their direct delivery to the appropriate cells of the immune system, thereby enhancing the effectiveness of vaccines by generating strong and broadly based immune responses. The resulting immune responses are expected to be much stronger and more rapid than with vaccines delivered by conventional means. The Company's liposomal formulations are also expected to minimise the side effects of vaccination as a result of the containment and slow release of the active materials. 

Commenting on this announcement, M. Scott Maguire, CEO of Lipoxen, said:

'The scourge that is malaria causes a death every 30 seconds in Africa alone. With funding from PATH we will explore whether our technology is suitable for malaria vaccines. The decision by NIAID, a world-leading biomedical research organization, to participate in this project will unquestionably accelerate this exploration.

'Lipoxen has other globally important vaccine candidates in its pipeline - including one against HIV. 2.1 million deaths in 2007 were attributed to HIV infection; this equates to 4 deaths per minute. The Company is also working alongside the International AIDS Vaccine Initiative (IAVI), the world's leading AIDS vaccine organization, on the improved delivery of HIV vaccine candidates. This is yet another externally funded research project with considerable potential to alleviate suffering in the developing world and beyond We also have a novel influenza vaccine candidate in development that has recently produced positive results in preclinical studies.

'Our Company is rapidly building a reputation in the field of novel vaccine development and delivery and each of these projects demonstrate Lipoxen's desire and commitment to help solve some of the gravest problems afflicting humanity.'

- Ends -

For further information please contact:

Lipoxen plc

+44 (0)20 7691 3583 

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång 

Noble & Company

+44 (0) 20 7763 2200 

John Llewellyn-Lloyd / Sam Reynolds  

Buchanan Communications

+44 (0)20 7466 5000

Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen

Notes for Editors


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms:

  • PolyXen - for extending the efficacy and half life of biologic drugs

  • ImuXen - for creating new vaccines and improving existing vaccines

  • SiRNAblate - for the delivery of siRNA

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products.  

Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes Factor XIII and vaccines against HIV, influenza and malaria.  

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, Genentech, Amgen and Genzyme.  

Lipoxen, which was founded in 1997, now trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website:

On the Internet: 

PATH Malaria Vaccine Initiative,


This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words 'targets', 'believes', 'estimates', 'expects', 'aims', 'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Among the important factors that could cause the Company's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to The Company's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

This information is provided by RNS
The company news service from the London Stock Exchange